Evaluation of Optimal Number of Neoadjuvant Chemotherapy Cycles and Cytoreductive Surgery in Women with Ovarian Cancer

被引：0
|
作者：
Shahrzad Sheikh Hassani
Somayeh Moradpanah
Setare Akhavan
Azamsadat Mousavi
Narges Zamani
Elahe Rezayof
机构：
[1] Tehran University of Medical Sciences,Department of Obstetrics and Gynecology
[2] Ziaeian Hospital,Department of Obstetrics and Gynecology
[3] Tehran University of Medical Sciences,Department of Gynecology Oncology
[4] Tehran University of Medical Sciences,undefined
[5] Vali-E-Asr Reproductive Health Research Center,undefined
[6] Family Health Research Institute,undefined
[7] Tehran University of Medical Sciences,undefined
来源：
Indian Journal of Gynecologic Oncology | 2024年 / 22卷
关键词：
Ovarian cancer; Neoadjuavnt chemotherapy; Interval debulking surgery; CA-125;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Evaluation of Optimal Number of Neoadjuvant Chemotherapy Cycles and Cytoreductive Surgery in Women with Ovarian Cancer
    Hassani, Shahrzad Sheikh
    Moradpanah, Somayeh
    Akhavan, Setare
    Mousavi, Azamsadat
    Zamani, Narges
    Rezayof, Elahe
    [J]. INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 22 (01)
  • [2] Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer
    Minareci, Yagmur
    Sozen, Hamdullah
    Ak, Naziye
    Tosun, Ozgur A.
    Saip, Pinar
    Salihoglu, M. Yavuz
    Topuz, Samet
    [J]. CHEMOTHERAPY, 2022, 67 (01) : 1 - 11
  • [3] Neoadjuvant chemotherapy and cytoreductive surgery in epithelial ovarian cancer
    Siriwan Tangjitgamol
    Jitti Hanprasertpong
    Marta Cubelli
    Claudio Zamagni
    [J]. World Journal of Obstetrics and Gynecology, 2013, (04) : 153 - 166
  • [4] Correct timing of cytoreductive surgery and chemotherapy in ovarian cancer: Neoadjuvant chemotherapy
    Pignata, S
    Tambaro, R
    [J]. TUMORI JOURNAL, 2003, : S37 - S37
  • [5] The Effect of Number of Neoadjuvant Chemotherapy Cycles on Pathologic Complete Response at Time of Interval Cytoreductive Surgery in Epithelial Ovarian Cancer Patients
    Gentry, Zachary
    Foxall, Mckenzie
    Harrelson, Alexander
    Wall, Jaclyn
    Arend, Rebecca C.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S329 - S329
  • [6] Neoadjuvant chemotherapy without a fixed number of cycles in advanced ovarian cancer not candidates for optimal primary surgery.
    Mendiola, Cesar
    Manneh, Ray
    Pascual, Tomas
    De Velasco, Guillermo
    Vega, Estela
    Manso, Luis
    Ghanem, Ismael
    Ciruelos, Eva M.
    Seoane, J.
    Cortes-Funes, Hernan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Neoadjuvant chemotherapy combined with interval cytoreductive surgery in ovarian cancer
    Du, Xinjie
    Lin, Xiaojie
    [J]. JOURNAL OF BUON, 2019, 24 (05): : 2035 - 2040
  • [8] Neoadjuvant chemotherapy/cytoreductive surgery/intraperitoneal chemotherapy for ovarian cancer: A feasibility assessment
    Scamon, L. G.
    Richard, S. D.
    Mcbee, W. C.
    Lesnock, J. L.
    Hurt, J. D.
    O'Malley, D. M.
    Krivak, T. C.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S143 - S143
  • [9] Standardization of cytoreductive surgery is a precondition for clinical trials of ovarian cancer including cytoreductive surgery and/or neoadjuvant chemotherapy
    Lim, Myong Cheol
    Park, Sang-Yoon
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 125 (02) : 510 - 510
  • [10] Factors that predict optimal debulking at interval cytoreductive surgery after neoadjuvant chemotherapy in epithelial ovarian cancer
    Boccaccio, R. B.
    Crim, A. K.
    Osborn, K.
    Ding, K.
    Moore, K. N.
    [J]. GYNECOLOGIC ONCOLOGY, 2018, 149 : 82 - 82
12345